News
STTK
6.85
+9.42%
0.59
Shattuck Labs Price Target Raised to $11.00/Share From $8.00 by Wedbush
Dow Jones · 1d ago
Shattuck Labs Is Maintained at Outperform by Wedbush
Dow Jones · 1d ago
Shattuck Labs price target raised to $11 from $8 at Wedbush
TipRanks · 1d ago
Wedbush Maintains Outperform on Shattuck Labs, Raises Price Target to $11
Benzinga · 1d ago
SL-325 Data Catalysts and Phase 2 Launch Plans Underpin Buy Rating on Shattuck Labs
TipRanks · 2d ago
Shattuck Labs reports Q1 EPS (13c), consensus (13c)
TipRanks · 2d ago
Shattuck Labs sees cash and cash equivalents sufficient into 2029
TipRanks · 2d ago
Shattuck Labs posts corporate deck outlining DR3 antibody SL-325 for inflammatory diseases
PUBT · 2d ago
Shattuck Labs Q1 net loss widens as R&D spends rise
Reuters · 3d ago
Shattuck Labs Q1 EPS $(0.13), Inline
Benzinga · 3d ago
Shattuck Labs GAAP EPS of -$0.13 in-line
Seeking Alpha · 3d ago
*Shattuck Labs 1Q Rev $0.00 >STTK
Dow Jones · 3d ago
Shattuck Labs Q1 FY26 net loss widens to $14.8 million; R&D expenses rise to $10.9 million
PUBT · 3d ago
SHATTUCK LABS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS
Reuters · 3d ago
*Shattuck Labs 1Q Loss/Shr 13c >STTK
Dow Jones · 3d ago
Press Release: Shattuck Labs Reports First -2-
Dow Jones · 3d ago
Press Release: Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights
Dow Jones · 3d ago
Weekly Report: what happened at STTK last week (0427-0501)?
Weekly Report · 6d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 04/29 21:06
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL) and Shattuck Labs (STTK)
TipRanks · 04/29 10:00
More
Webull provides a variety of real-time STTK stock news. You can receive the latest news about Shattuck Labs, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About STTK
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.